Alendronate and/or Parathyroid Hormone for Osteoporosis

Launched by MASSACHUSETTS GENERAL HOSPITAL · Nov 3, 1999

Keywords

ClinConnect Summary

This is a randomized, prospective, open-label study in which osteoporotic postmenopausal women self-administer synthetic hPTH-(1-34), alendronate, or both, every day for 2.5 years. Participants initially come to Massachusetts General Hospital once a month, and subsequently once every 3-6 months, for measurements of serum and urine indices of bone formation and resorption, serum and urine toxicity tests, and DXA/QCT measurements of bone mass. One-third of the participants take hPTH-(1-34) daily, one-third take alendronate once daily, and one-third take both daily (Phase A, months 0-30).

Par...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Lumbar spine or hip BMD T-score less than or equal to minus 2.0
• • Postmenopausal at least 5 years
• • Fully ambulatory
• • Able to give informed consent
• Exclusion Criteria:
• • No concurrent illnesses that cause bone loss
• • No recent drug treatment for osteoporosis
• • No recent fracture